Literature DB >> 25424440

Effect of everolimus on polycystic liver volume in autosomal dominant polycystic kidney disease.

Stefan Zschiedrich1, Klemens Budde, Gerd Walz.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25424440     DOI: 10.1007/s10157-014-1059-x

Source DB:  PubMed          Journal:  Clin Exp Nephrol        ISSN: 1342-1751            Impact factor:   2.801


× No keyword cloud information.
  4 in total

1.  The long-term outcome of patients with polycystic liver disease treated with lanreotide.

Authors:  M Chrispijn; F Nevens; T J G Gevers; R Vanslembrouck; M G H van Oijen; W Coudyzer; A L Hoffmann; H M Dekker; R A de Man; L van Keimpema; J P H Drenth
Journal:  Aliment Pharmacol Ther       Date:  2011-11-24       Impact factor: 8.171

2.  Everolimus in patients with autosomal dominant polycystic kidney disease.

Authors:  Gerd Walz; Klemens Budde; Marwan Mannaa; Jens Nürnberger; Christoph Wanner; Claudia Sommerer; Ulrich Kunzendorf; Bernhard Banas; Walter H Hörl; Nicholas Obermüller; Wolfgang Arns; Hermann Pavenstädt; Jens Gaedeke; Martin Büchert; Christoph May; Harald Gschaidmeier; Stefan Kramer; Kai-Uwe Eckardt
Journal:  N Engl J Med       Date:  2010-06-26       Impact factor: 91.245

3.  Everolimus does not further reduce polycystic liver volume when added to long acting octreotide: results from a randomized controlled trial.

Authors:  Melissa Chrispijn; Tom J G Gevers; Jeroen C Hol; Rene Monshouwer; Heleen M Dekker; Joost P H Drenth
Journal:  J Hepatol       Date:  2013-03-14       Impact factor: 25.083

4.  Sirolimus reduces polycystic liver volume in ADPKD patients.

Authors:  Qi Qian; Hui Du; Bernard F King; Sumedha Kumar; Patrick G Dean; Fernando G Cosio; Vicente E Torres
Journal:  J Am Soc Nephrol       Date:  2008-01-16       Impact factor: 10.121

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.